Biomarkers in COPD
Biomarkers in COPD
复制标题
DOI：
10.1016/j.pupt.2010.05.001
复制
发表时间：
2010-12-01
影响因子：
3.2
通讯作者：
Novelli, Giuseppe
中科院分区：
文献类型：
--
作者：
Cazzola, Mario;Novelli, Giuseppe
尽管人们对使用肺生物标记物对COPD进行更完整和临床相关的评估越来越感兴趣，并且有大量的生物标记物可用，但关于它们的重复性和与COPD其他结果测量的相关性的信息很少。缺乏有效的生物标记物可用于监测疾病活动、预测未来临床结果和治疗干预措施的效果，这突显了在COPD中确定新的生物标记物的事实必要性。综合功能信息学是不同技术(基因组学、蛋白质组学、代谢组学和代谢组学、药物遗传学和综合方法)的接口和集成的一个新方向，用来收集和分析有关生物标记物的数据，我们很可能能够识别出COPD的可靠、可靠和可重复性的生物标记物。(C)2010爱思唯尔有限公司。保留所有权利。
Although there is increasing interest in using pulmonary biomarkers for a more complete and clinically relevant assessment of COPD and a plethora of biomarkers are becoming available, there is little information regarding their reproducibility and correlation with other outcome measurements in COPD. The lack of well-validated biomarkers that can be used for monitoring disease activity, predicting future clinical outcomes and the effect of therapeutic interventions highlights the factual need to identify new biomarkers in COPD. It is likely that, using what is called 'integrative functional informatics', which is a novel direction in the interfacing and integration of different technologies (genomics, proteomics, metabolomics and metabonomics, pharmacogenetics, and integrative approaches) for collection and analysis of data on biomarkers, we will be able to identify robust, reliable, and reproducible biomarkers in COPD. (C) 2010 Elsevier Ltd. All rights reserved.